+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Global Ulcerative Colitis Market - Growth, Trends, and Forecasts 2017 - 2022

  • ID: 4388606
  • Report
  • Region: Global
  • 120 pages
  • Mordor Intelligence
until Dec 31st 2019
1 of 3
The global ulcerative colitis market accounted for USD 5,200 million in 2015 and is expected to reach USD 5,450 million by 2016. The market is expected to reach USD 6,798 million by 2021, growing at a CAGR of 4.52% during the forecast period from 2016 to 2021.

According to the US Center for Disease Control, there is an ulcerative colitis prevalence of 238 per 100,000 adults. The number of ulcerative colitis patients is increasing in emerging economies.

Global Ulcerative Colitis Market-Market Dynamics

The report details several factors driving and restraining the market, some of which are listed below.


Increasing patient pool with unmet needs

New drugs entering the market

Increasing global incidence & prevalence rate

Increasing investments towards research in small molecules


Blockbuster drugs losing patent protection and increasing the propensity for generic drugs are turning out to be restraints for the market.

The ulcerative colitis market has been segmented based on monoclonal antibodies, pharmaceuticals, and biosimilars. The segment on monoclonal antibodies includes Humira, Simponi, Remicade, and Entyvio. The segment on pharmaceuticals has been further segmented into Mesalamine, Balsalazide, and Budesonide (Uceris).The mesalamine drug includes Asacol HD, Pentasa, Lialda, and sfRowasa. The Balsalazide includes Colazal and Giazo.

Geographically, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America includes the US, Canada, and Mexico. The Europe segment includes the UK, Germany, France, Spain, Italy, Scandinavia, BENELUX, and Rest of Europe. The Asia-Pacific segment includes Japan, China, India, South Korea, Australia & New Zealand and Rest of Asia-Pacific.

The lack of curative therapy and personalized therapy are big opportunities for the market. North America, especially the US, accounted for the largest market share. The Europe and Asia-Pacific markets are expected to grow at a higher CAGR during the forecast period. In Asia-Pacific, China leads the market. Economic development and betterment of healthcare facilities are propelling the growth of the market. The entry of Simponi and Entyvio is likely to fuel the growth of the market. However, Humira will lose its patent in 2016 and Remicade in 2018 and will not have a positive impact on the market.

Major Companies in the Sector Include:

This Report Offers:

Market analysis for the global ulcerative colitis market, with region-specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the global ulcerative colitis market.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study deliverables
1.2 Market definition
1.3 Study assumptions
2. Research methodology
2.1 Introduction
2.2 Analysis methodology
2.3 Study timeline
2.4 Study phases
2.4.1 Secondary research
2.4.2 Discussion guide
2.4.3 Market engineering & econometric model
2.4.4 Expert validation
3. Executive summary
4. Key inferences
5. Market overview and industry trends
5.1 Current market scenario
5.2 Porter's five forces
5.2.1 Bargaining power of suppliers
5.2.2 Bargaining power of consumers
5.2.3 Threat of new entrants
5.2.4 Threat of substitute products and services
5.2.5 Competitive rivalry within the industry
6. Market dynamics
6.1 Market drivers
6.1.1 High patient pool with unmet need
6.1.2 New drugs entering market
6.1.3 Increasing global incidence & prevalence
6.1.4 Increasing research for small molecules
6.2 Market restraints
6.2.1 drugs losing patent protection
6.2.2 Increasing prescription trends for generic drugs
6.3 Market opportunity
6.3.1 Lack of curative drugs
6.3.2 Personalized therapy
6.4 Market challenge
7. Market segmentation
7.1 By products
7.1.1 Monoclonal Antibodies Humira (Adalimumab) Simponi (Golimumab) Remicade (Infliximab) Entyvio (Vedolizumab)
7.1.2 Pharmaceuticals Mesalamine Asacol HD Pentasa Lialda sfRowasa Balsazide Colazal Giazo Budesonide (Uceris)
7.1.3 Biosimilars
8. Segmentation by geography
8.1 North America
8.1.1 US
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 UK
8.2.2 Germany
8.2.3 France
8.2.4 Spain
8.2.5 Italy
8.2.6 Scandinavia
8.3 Asia-Pacific
8.3.1 Japan
8.3.2 China
8.3.3 India
8.3.4 South Korea
8.3.5 Australia & New Zealand
8.3.6 Rest of Asia-Pacific
8.4 Rest of the World
8.4.1 Middle East & Africa
8.4.2 South America
9. Company profiles
9.1 AbbVie
9.2 Takeda Pharmaceuticals
9.3 Roche
9.4 Warner Chilcott
9.5 Johnson and Johnson
9.6 AstraZeneca
9.7 Shire Pharmaceuticals
9.8 Pfizer
9.9 Merck
9.10 Eisai
10. Analyst outlook for investment opportunity
11. Future outlook of the market
Note: Product cover images may vary from those shown
3 of 3